BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
ALPHASIMPLEX GROUP, LLC 23,223$1,868,0000.85%
Ipswich Investment Management Co., Inc. 31,985$2,572,0000.82%
Carmichael Hill & Associates, Inc. 15,000$1,206,0000.80%
Marks Group Wealth Management, Inc 53,796$4,326,0000.78%
BEESE FULMER INVESTMENT MANAGEMENT, INC. 68,228$5,487,0000.78%
Blueshift Asset Management, LLC 69,016$5,550,0000.76%
Decatur Capital Management, Inc. 47,386$3,811,0000.75%
MARATHON ASSET MANAGEMENT LLP 581,673$46,930,0000.74%
MACKENZIE FINANCIAL CORP 3,633,199$292,182,0000.73%
MONETA GROUP INVESTMENT ADVISORS LLC 100,970$8,120,0000.71%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 6,853,390$551,150,0000.70%
Colonial Trust Advisors 53,629$4,313,0000.68%
HUNTINGTON NATIONAL BANK 572,917$46,073,0000.67%
HORIZON BANCORP INC /IN/ 5,827$469,0000.66%
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL 17,992$1,447,0000.66%
Neo Ivy Capital Management 8,063$648,0000.66%
TRUST CO OF TOLEDO NA /OH/ 36,362$2,924,0000.65%
WHITENER CAPITAL MANAGEMENT, INC. 16,792$1,350,0000.65%
Cairn Investment Group, Inc. 7,630$613,0000.65%
FRG Family Wealth Advisors LLC 32,665$2,627,0000.64%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.